How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. · 2021

Read How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? by Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7886759.txt.

Introduction

Geng and co-authors present a review of how fat build-up harms the liver in non-alcoholic fatty liver disease. Extra lipid in the liver is not caused by alcohol in this disease. The harm done by that lipid is called lipotoxicity. The review explains how a mild fatty liver can progress to the inflamed form known as NASH.

The authors focus on free fatty acids and where they end up in liver cells. An imbalance between fat coming in and fat being burned or shipped out shifts many lipid species. Those shifts strain cell parts such as the endoplasmic reticulum and mitochondria. Stress signals switch on, and cells can die. The review maps these steps in detail. It gives readers a clear account of how simple fat storage turns into active liver damage.

Catalog record

CREATORGeng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE65 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7886759

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? By Yana Geng, Klaas Nico Faber, Vincent E de Meijer, Hans Blokzijl, Han Moshage Published in: Hepatology International DOI: 10.1007/s12072-020-10121-2 ABSTRACT Abstract Background Non-alcoholic fatty liver disease (NAFLD), characterized as excess lipid accumulation in the liver which is not due to alcohol use, has emerged as one of the major health problems around the world. The dysregulated lipid metabolism creates a lipotoxic environment which promotes the development of NAFLD, especially the progression from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). Purposeand Aim This review focuses on the mechanisms of lipid accumulation in the liver, with an emphasis on the metabolic fate of free fatty acids (FFAs) in NAFLD and presents an update on the relevant cellular processes/mechanisms that are involved in lipotoxicity. The changes in the levels of various lipid species that result from the imbalance between lipolysis/lipid uptake/lipogenesis and lipid oxidation/secretion can cause organellar dysfunction, e.g. ER stress, mitochondrial dysfunction, lysosomal dysfunction, JNK activation, secretion of extracellular vesicles (EVs) and aggravate (or be exacerbated by) hypoxia which ultimately lead to cell death. The aim of this review is to provide an overview of how abnormal lipid metabolism leads to lipotoxicity and the cellular mechanisms of lipotoxicity in the context of NAFLD. Keywords: NAFLD, NASH, MAFLD, Free fatty acids, Lipotoxicity, Lipid metabolism, Cell death, ER stress, Mitochondrial dysfunction, JNK INTRODUCTION In line with the global epidemic of obesity and type 2 diabetes mellitus (T2DM) the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing throughout the world. Recently, a new definition of NAFLD was suggested by a panel of international experts: Metabolic Associated Fatty Liver Disease (MAFLD), which contains “positive criteria” and is independent of alcohol use to diagnose the disease [1]. However, considering that the majority of studies referred to in this review were based on criteria of NAFLD, we decided to use the nomenclature of NAFLD in the current review. NAFLD is the most common liver disorder in Western countries with a prevalence of approximately 25% [2]. It is characterized by excessive hepatic lipid deposition (steatosis) in the absence of excessive alcohol use or alternative causes. The spectrum of NAFLD ranges from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH), fibrosis and ultimately cirrhosis with its known complications, such as decompensation and/or hepatocellular carcinoma [3]. From 2003 to 2014 NASH was the most rapidly growing indication for liver transplantation in the United States [4]. In the near future, NASH will become the leading indication for liver transplantation [5]. NAFLD is recognized as the hepatic manifestation of the metabolic syndrome. Abundant data link NAFLD with abdominal obesity, T2DM, hypertension and atherogenic dyslipidemia which are risk factors for cardiovascular disease (CVD) [6, 7]. Mortality in patients with NAFLD is mainly attributed to increased risk of death due to CVD and liver-related death. Fibrosis stage predicted both overall and disease-specific mortality [8]. From a clinical point of view, the full understanding of the mechanisms underlying the development of NAFLD and NASH is of extreme importance to treat the hepatic and extrahepatic complications of NAFLD. It is now generally recognized that the development of NAFLD is a multifactorial process. Apart from obesity and T2DM, which are two important factors commonly associated with NAFLD, environmental and genetic factors, as well as gut microbiota, are likely to play a role in the onset and progression of NAFLD [3, 9, 10]. A thorough discussion of the role of microbiota and NAFLD is outside the scope of this review and has been reviewed recently [11]. Thus, both the pathophysiological mechanisms leading to disease and the clinical manifestations are highly heterogeneous. Hepatic steatosis results from an imbalance between synthesis and utilization of lipids. Dysregulation of lipid homeostasis in hepatocytes leads to the generation of toxic lipids that result in dysfunctional organelles promoting inflammation, hepatocellular damage and cell demise [8]. Elucidating the pathways leading to lipotoxicity-induced cell injury may lead to the development of new therapeutic options. Thus, the various pathways involved in hepatic fat accumulation and lipid toxicity contributing to the pathogenesis of NAFLD and eventually end-stage liver disease are discussed below. METABOLIC CHANGES OF LIPIDS IN NON-ALCOHOLIC FATTY LIVER DISEASE Lipolysis of adipose tissue Most NAFLD patients have increased white adipose tissue (WAT) mass and its expansion is a high-risk factor in the progression of NAFLD [12, 13]. Human studies have shown that the shift of fat storage from subcutaneous to visceral adipose tissue is associated with liver damage [12, 14] and the expansion of visceral adipose tissue may be a powerful predictor for NAFLD. Nonetheless, determining whether the liver damage is associated with the changes in the fatty acid composition of adipose tissues needs more study [15]. As the main source of circulating lipids, the increased secretion of FFAs from adipose tissue is strongly associated with enhanced lipolysis, in particular increased triglyceride (TG) hydrolysis. Obese NAFLD patients demonstrated greater lipolysis in adipose tissue, which may account for 60–70% of fat accumulating in the liver [16]. The excessive lipolysis of adipose tissue is accompanied with abnormal production of hormones released by adipocytes (e.g. reduced production of adiponectin) and adipose tissue inflammation (e.g. the release of pro-inflammatory cytokines), all of which participate in promoting insulin resistance (IR), thus further contributing to ectopic fat deposition [17, 18]. In addition to the cytosolic lipolysis, lipophagy is an alternative way of TG hydrolysis. As a form of autophagy, specifically macroautophagy, lipophagy mediates the hydrolysis of TG stored in lipid droplets via fusion of the engulfed droplets with lysosomes. Of note, the contribution of lipophagy to the catabolism of TG is more prominent in brown adipose tissue and the liver compared to WAT [19]. Moreover, NAFLD patients, subjected to chronic lipid exposure, exhibit an inhibited lipophagy, whereas an acute addition of lipids to cells in vitro may enhance lipophagy, which might be an adaptive response. In addition, FFAs derived from the efflux from other cell types, for example, hepatocytes, as well as FFAs released from TG-rich lipoproteins by lipoprotein lipase (LPL), are also sources of circulating FFAs (Fig. 1). [Figure: Hepatic lipid metabolism in NAFLD. Dietary lipids are mainly absorbed in the intestine and incorporated into intestinal chylomicrons (intestinal CMs) and then transported to adipose tissue and the liver via the bloodstream. In adipose tissue, intestinal CMs are taken up and stored in lipid droplet. In NAFLD, the hydrolysis of TG is largely enhanced in adipocytes. TG is hydrolyzed into diacylglycerol (DAG), monoacylglycerol (MAG) and glycerol, releasing one fatty acid in each step. The increased fatty acid load is then delivered to the liver, scavenged by fatty acid translocase (FAT/CD36), fatty acid transport proteins (FATPs) and caveolins and incorporated into lipid droplets. In hepatocytes, de novo lipogenesis is increased which contributes to the lipid pool as well. On the other hand, fatty acids are oxidized in mitochondria (mitochondrial β-oxidation), peroxisomes (peroxisomal β-oxidation) and microsomes (microsomal ω-oxidation), accompanied by an elevated production of ROS. The secretion of TG-enriched very-low-density lipoprotein (VLDL) is another route of lipid disposal. It is increased in absolute terms, but its increase does not match the increased fat accumulation in NAFLD. Arrows (red) indicate the up- or down-expressions of specific proteins in NAFLD. CPT1/2 carnitine palmitoyltransferase

Read the complete text